Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Terence Friedlander, MD, shares a look at an upcoming program reviewing recent, significant data from the EV-302/KEYNOTE-A39 study.
Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.
Expert oncologist Aditya Bardia, MD, shares his excitement for an upcoming program centered on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.
Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...